Alto Neuroscience Replicates EEG Biomarker in Robust Clinical Study

Alto Neuroscience, a clinical-stage biopharmaceutical company, has announced robust replication of an EEG biomarker through its Precision Psychiatry Platform. The platform utilizes data science and analytics to identify brain-based biomarkers for psychiatric conditions. The company's pipeline includes five clinical-stage assets targeting depressive disorder and schizophrenia populations.

Alto Neuroscience, a clinical-stage biopharmaceutical company, has announced the robust replication of an electroencephalography (EEG) biomarker through its Precision Psychiatry Platform. This platform leverages data science and analytics to identify brain-based biomarkers for psychiatric conditions. The company's pipeline includes five clinical-stage assets targeting depressive disorder and schizophrenia populations.

The announcement is based on an independent, prospective replication study evaluating EEG biomarkers in people with schizophrenia. The study, which involved 155 individuals with schizophrenia and 272 healthy controls, successfully replicated previous findings. Event-related theta-band responses, particularly theta-band inter-trial coherence (ITC), were found to robustly differentiate patients with schizophrenia from healthy individuals [1].

Theta ITC demonstrated greater case-control differences compared to traditional schizophrenia EEG measures, marking an independent replication supporting its role as the most robust measure of schizophrenia neurobiology. The study also observed a statistically significant correlation between theta ITC and cognitive performance, further strengthening the foundation for using theta ITC as a primary outcome measure in Alto’s ongoing Phase 2 trial of ALTO-101 in patients with Cognitive Impairment Associated with Schizophrenia (CIAS) [2].

The findings indicate that EEG measures of theta ITC and event-related spectral perturbation (ERSP) showed the largest differences between patients with schizophrenia and healthy controls, outperforming traditional EEG and event-related potential measures. Both theta ITC and ERSP were also significantly correlated with processing speed, a key domain of cognitive impairment in schizophrenia.

Alto Neuroscience expects to publish full details of this analysis through upcoming medical conferences or peer-reviewed publications. The company aims to bring objectivity and precision to complex conditions like schizophrenia by using theta ITC as a reliable, non-invasive approach to identify specific patient populations and measure the effects of targeted therapies.

References:
[1] https://www.businesswire.com/news/home/20250909814928/en/Alto-Neuroscience-Announces-Robust-Replication-of-EEG-Biomarker-to-Objectively-Identify-Patients-with-Cognitive-Impairment-in-Schizophrenia
[2] https://www.morningstar.com/news/business-wire/20250909814928/alto-neuroscience-announces-robust-replication-of-eeg-biomarker-to-objectively-identify-patients-with-cognitive-impairment-in-schizophrenia